$7.01
GoodRx is now publicly available to trade. The stock opened at $46, nearly 40% above it's IPO price of $33.
Launched in 2011, GoodRx allows customers to compare prescription drug prices. It's since become a household name, which may be one of the reasons that the stock has been getting so much buzz. If you're planning to invest, here's how you can buy in.
How to buy shares in GoodRx
- Choose a platform. If you're a beginner, our stock trading platform picks below can help you choose.
- Open your account. Provide your personal information and sign up.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: GDRX in this case.
- Research stocks. The platform should provide the latest information available.
- Buy your stocks. Place a market order or limit order with your preferred number of shares. It's that simple.
Our top picks for buying GoodRx stock
- Earn 5.25% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Trade stocks, bonds, options, ETFs, crypto, Treasurys, collectibles, royalties
- Earn 5.1% APY on your cash
- Earn a $0.18 rebate on options, with no commissions and no per-contract fees
- Trade stocks, options and ETFs without commissions
- Innovative social trading features
- FINDER EXCLUSIVE: Get a guaranteed $15 bonus when you sign up and deposit $100
Is it a good time to buy GoodRx stock?
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Share price volatility
Over the last 12 months, GoodRx's shares have ranged in value from as little as $4.135 up to $9.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GoodRx's is 1.444. This would suggest that GoodRx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Historical closes compared with the last close of $7.06
1 week (2024-03-19) | 3.82% |
---|---|
1 month (2024-02-26) | 7.13% |
3 months (2023-12-26) | 8.45% |
6 months (2023-09-26) | 29.30% |
1 year (2023-03-26) | 14.80% |
2 years (2022-03-24) | -58.79% |
3 years (2021-03-25) | -81.44% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Buy GoodRx stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is GoodRx under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the GoodRx P/E ratio, PEG ratio and EBITDA
GoodRx's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $67 million.
The EBITDA is a measure of a GoodRx's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
- Teva Pharma Industries Ltd ADR (TEVA.US): USD$4.3 billion
- Teladoc (TDOC.US): USD$46.2 million
- Humana (HUM.US): USD$4.9 billion
Frequently asked questions
More guides on Finder
-
How to buy Zentek stock
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
-
How to buy Mainz Biomed stock
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
-
How to buy ATAI Life Sciences stock
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
-
How to buy Owlet Baby Care stock
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
-
How to buy Eli Lilly and Company stock
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
-
How to buy Humana stock
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
-
How to buy Illumina stock
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
-
How to buy UnitedHealth Group Incorporated stock
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
-
How to buy Pfizer stock
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
-
How to buy Johnson-and-Johnson stock
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Ask a Question